TY  - JOUR
KW  - Side effects
KW  -  COVID-19 vaccines
KW  -  Long-term
KW  -  Heterogenous
KW  -  Bangladesh
SN  - 2045-2322
A1  - Sharif, Nadim
A1  - Opu, Rubayet Rayhan
A1  - Saha, Tama
A1  - Khan, Afsana
A1  - Aljohani, Abrar
A1  - Alsuwat, Meshari A.
A1  - García, Carlos O.
A1  - Vázquez, Annia A.
A1  - Alzahrani, Khalid J.
A1  - Miramontes-González, J. Pablo
A1  - Dey, Shuvra Kanti
VL  - 14
IS  - 1
Y1  - 2024/10//
UR  - http://doi.org/10.1038/S41598-024-75833-Z
TI  - Side effects associated with homogenous and heterogenous doses of Oxford?AstraZeneca vaccine among adults in Bangladesh: an observational study
JF  - Scientific Reports
N2  - Assessment of side effects associated with COVID-19 vaccination is required to monitor safety issues and acceptance of vaccines in the long term. We found a significant knowledge gap in the safety profile of COVID-19 vaccines in Bangladesh. We enrolled 1805 vaccine recipients from May 5, 2021, to April 4, 2023. Kruskal-Wallis test and ?2 test were performed. Multivariable logistic regression was also performed. First, second and third doses were administered among 1805, 1341, and 923 participants, respectively. Oxford?AstraZeneca (2946 doses) was the highest administered followed by Sinopharm BIBP (551 doses), Sinovac (214 doses), Pfizer-BioNTech (198 doses), and Moderna (160 doses), respectively. Pain at the injection site (80-90%, 3200?3600), swelling (85%, 3458), redness (78%, 3168), and heaviness in hand (65%, 2645) were the most common local effects, and fever (85%, 3458), headache (82%, 3336), myalgia (70%, 2848), chills (67%, 2726), muscle pain (60%, 2441) were the most prevalent systemic side effects reported within 48 h of vaccination. Thrombosis was only reported among the Oxford?AstraZeneca recipients (3.5-5.7%). Both local and systemic effects were significantly associated with the Oxford?AstraZeneca (p-value?<?0.05), Pfizer?BioNTech (p-value?<?0.05), and Moderna (p-value?<?0.05) vaccination. Chronic urticaria and psoriasis were reported by 55-60% of the recipients after six months or later. The highest percentage of local and systemic effects after 2nd and 3rd dose were found among recipients of Moderna followed by Pfizer-BioNTech and Oxford?AstraZeneca. Homogenous doses of Oxford?AstraZeneca and heterogenous doses of Moderna and Pfizer-BioNTech were significantly associated with elevated adverse effects. Females, aged above 60 years with preexisting health conditions had higher risks. Vaccination with Pfizer-BioNTech (OR 4.34, 95% CI 3.95?4.58) had the highest odds of severe and long-term effects followed by Moderna (OR 4.15, 95% CI 3.92?4.69) and Oxford?AstraZeneca (OR 3.89, 95% CI 3.45?4.06), respectively. This study will provide an integrated insight into the safety profile of COVID-19 vaccines.
AV  - public
ID  - uninimx15626
ER  -